by Thom King, Icon Foods, Chief Innovations Officer/Food Scientist In an era where health and wellness take center stage, the quest for sugar alternatives has led to remarkable advancements in food science. One noteworthy performer in this field is Icon Read more…
By Thom King – Chief Innovations Officer, Icon Foods When it comes to formulating for clean label sugar reduction, having multiple options for sweetening and flavor modulation is like having a party with all your favorite friends—each one brings something Read more…
By Kash Rocheleau and Thom King We appreciate your continued interest and loyalty in returning to read our thoughts on what’s happening in the industry. Before we dive in, allow me to introduce myself. I’m Kash, and I’ve had the Read more…
Steviva Brands No-Added Sugar Green Shamrock Shake Here’s a delightful recipe for a shamrock shake that’s both refreshing and free of added sugars, using KetoseSweet+ as a sweetener. This shake is perfect for celebrating St. Patrick’s Day or simply enjoying Read more…
Original article posted on Nutritional Outlook. Functional fiber blends by Icon Foods will be showcased at Expo West 2025 Article by Erin McEvoy, with insights from Icon Foods Digestive-friendly FibRefine 3.0 and Organic FibRefine 3.5 tolerably add up to 15g Read more…
By Thom King – Chief Innovations Officer Icon Foods Steviol glycosides, which are natural sweet constituents derived from the leaves of the Stevia Rebaudiana plant, have garnered considerable velocity as low-calorie sugar substitutes. This paper aims to provide an in-depth Read more…
Estimated Reading Time: 3 Minutes GLP-1 Medications, Keto, and Blood Sugar Control Like a medium rare rib eye with a pad butter floating on top, the naysayers of keto said stick a fork in it, keto is dead. Au contraire Read more…
By Thom King – Chief Innovations Officer Icon Foods Where does one even start? Tariffs? Cargill’s anti-dumping suit? Demand for containers? The only thing we are missing is a pandemic. We will dive into the burning dumpster in a bit Read more…
Semaglutide, commonly referred to as Ozempic[i], falls into drugs categories known as GLP-1 or Glucagon-like peptide-1 (GLP-1) agonists. Tirzepatide, commonly referred to at the brand Mounjaro[ii], falls into a dual agonist category which contain both GLP-1 and GIP, glucose-dependent insulinotropic Read more…
